Aims Multiple myeloma (MM) is an incurable hematological cancer with a higher rate of
relapse. Alterations in the function of long non-coding RNAs (lncRNAs) promote the …

Multiple myeloma (MM) is an incurable disease, whose clinical heterogeneity makes its
management challenging, highlighting the need for biological features to guide improved …

Abstract Background Long noncoding RNAs (lncRNAs) are involved in a wide range of
biological processes in tumorigenesis. However, the role of lncRNA expression in the …

This study aimed to explore the potential effects of novel non-coding ribose nucleic acids
(ncRNAs) in patients with multiple myeloma (MM). The gene expression profile of plasma …

Multiple myeloma (MM) is one of the three major malignancies of the hematological system
in middle‑aged and older individuals. The incidence of MM increases with age and due to its …

Long non-coding RNAs (lncRNAs) are non-protein-coding RNAs longer than 200
nucleotides. Accumulating evidence demonstrates that lncRNA is a potential biomarker for …

Multiple myeloma (MM) is the second most common hematooncological disease of
malignant plasma cells in the bone marrow. While new treatment brought unprecedented …

Transcripts longer than 200 nucleotides that are not translated into proteins are known as
long non-coding RNAs, or lncRNAs. Now, they are becoming more significant as important …

Background Dysregulated long non-coding RNAs (lncRNAs) have been found to have
oncogenic and/or tumor suppressive roles in the development and progression of cancer …

Multiple myeloma (MM) is a clonal proliferation of bone marrow plasma cells characterized
by highly heterogeneous genetic background and clinical course, whose pathogenesis …